Agta Record, BioAlliance, Boiron, Korian: French Equity Preview

The following is a list of companies whose stocks may have unusual price changes in Paris. Symbols are in parentheses after company names and prices are from the last close.

France’s CAC 40 Index (CAC) rose 3.6 percent to 3,073.18. The wider SBF 120 Index gained 3.6 percent to 2,360.24

Agta Record (AGTA FP): The maker of automatic doors said its first-half net income rose 46 percent to 4.6 million euros. Sales rose 5.8 percent. The shares advanced less than 0.1 percent to 24.71 euros.

Boiron SA (BOI) : The maker of homeopathic drugs was cut to “sell” from “buy” at Arkeon Finance, with a price estimate of 28 euros. The shares fell 25 percent to 20.10 euros.

BioAlliance Pharma (BIO FP): The drugmaker specializing in cancer and HIV treatment said it is taking back full control of rights in the U.S. for Oravig. The company said its sees no significant impact on revenue from the regained rights. Separately, it said it won French approval for Livatag Phase III. The shares rose 3.7 percent to 3.94 euros.

Eutelsat SA (ETL FP): The satellite operator said it signed a commercial accord with Eser Telekom in Turkey. The shares rose 4.3 percent to 30.86 euros.

Korian (KORI FP): The operator of retirement homes in France said first-half net income fell 28 percent to 5.8 million euros. Sales rose 9.7 percent to 485.6 million euros. The shares declined 1 percent to 14.50 euros.

Groupe PCAS (PCA FP): The developer of molecules for drugs, perfume, glass and other products said first-half net income fell to 2.2 million euros from 2.8 million euros. The shares slid 2.5 percent to 2.72 euros.

To contact the reporters on this story: Mark Deen in Paris at markdeen@bloomberg.net

To contact the editor responsible for this story: Vidya Root in Paris at vroot@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.